Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03324607 · ClinicalTrials.gov registry record · Phase 2

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

A Phase 2 study, sponsored by Bastiaan Driehuys.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT03324607: Completed Phase 2 study, sponsored by Bastiaan Driehuys.

NCT03324607 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03324607, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will be used as a new measure to determine change in function. The investigator anticipate these images will provide more specific information about lung disease than standard lung function tests in response to treatment.

Primary Outcome

The ventilation distribution as measured by ventilation defect+low percent is to measure the area of the lung that has no air.

Interventions

  • DRUG hyperpolarized 129Xe gas MRI
  • DRUG Bevespi Aerosphere

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-04-20
Est. Completion 2019-11-12
Phase Phase 2
Bastiaan Driehuys

16 total trials

What the finished NCT03324607 record still lists

NCT03324607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which hyperpolarized 129Xe gas MRI is the first listed.

NCT03324607 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03324607 about?

NCT03324607 is a clinical study titled "Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI". The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will be used as a new measure to determine change in function. The...

What is the current status of trial NCT03324607?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-04-20. Estimated completion is 2019-11-12.

What interventions are being tested in trial NCT03324607?

The interventions under investigation include: hyperpolarized 129Xe gas MRI (DRUG), Bevespi Aerosphere (DRUG).

Who is sponsoring clinical trial NCT03324607?

This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03324607's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03324607, the US trial registry maintained by the National Library of Medicine. NCT03324607 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.